Dermata Therapeutics, Inc. DRMAW
0.00 USD 0.00 (-50.00%)
Aug 17, 2026, 11:53 AM EDT
0.0005 Day range 0.0011
0.0005 52-week range 0.0011
- YTD
- -96.81%
- 1 year
- -96.81%
News
benzinga.com Dermata Therapeutics Secures Australian Patent Acceptance For Bioneedle System In Dermal Fillers - This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers -- The Company also has allowed and issued patents in the US,…
benzinga.com Dermata Therapeutics Announces Private Placement Up To $12.4M Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced that it has entered into definitive agreements…
accessnewswire.com A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity SAN DIEGO, CA / ACCESS Newswire / December 4, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today…
benzinga.com Dermata Therapeutics Announces Australian Patent Office Accept Patent Application For Spongilla Technology Combination As Method For Treating Acne - This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to topically treat acne -- Dermata expects to launch a new once-weekly,…
benzinga.com Dermata Therapeutics Announces Strategic Pivot To Prioritize Development And Distribution Of OTC Pharmaceutical Dermatology Focused Products Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced a bold strategic pivot to prioritize the…
benzinga.com Dermata's XYNGARI Phase 3 Trial Hits Statistically Significant Difference At 4 Weeks - Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -- Additional data analysis revealed that…